Solange Peters

Research interests

Publications

• Tumour mutational burden: clinical utility, challenges and emerging improvements

  Nature Reviews Clinical Oncology · 2024 · https://doi.org/10.1038/s41571-024-00932-9

• Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

  Cell · 2024 · 10.1016/j.cell.2024.02.041

• Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2022.12.009

• Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00221-0

• Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2022.12.013

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.001

• Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00518-6

• ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.07.1941

• Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

  Journal of Thoracic Oncology · 2022 · https://doi.org/10.1016/j.jtho.2022.10.003

• Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.02.024

• EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.07.016

• Overcoming therapy resistance in EGFR-mutant lung cancer

  Nature Cancer · 2021 · 10.1038/s43018-021-00195-8

• Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02212

• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30314-4

• Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00793

• Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.04.478

• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

  The Lancet · 2020 · 10.1016/s0140-6736(20)31187-9

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1910231

• Gender medicine and oncology: report and consensus of an ESMO workshop

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz414

• Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

  Annals of Oncology · 2018 · 10.1093/annonc/mdy495

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2018 · 10.1093/annonc/mdy275

• Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.2292

• Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy554

• Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

  The Lancet Respiratory Medicine · 2017 · https://doi.org/10.1016/s2213-2600(17)30129-7

• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1613493

• Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1704795

• EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

  Annals of Oncology · 2017 · 10.1093/annonc/mdx221

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · 10.1093/annonc/mdx225

• Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.6095

• Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2012 · 10.1093/annonc/mds226

Current projects

No projects listed.